Jefferies analyst Dennis Ding downgraded Amphastar (AMPH) to Hold from Buy with a price target of $22, down from $30. Despite what the firm calls an “inexpensive valuation,” it cites a lack of meaningful upside catalysts and new launches being “less impactful than expected” for its downgrade.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMPH:
- Amphastar price target lowered to $23 from $30 at Barclays
- Amphastar Expands Share Repurchase Authorization to Manage Equity
- Amphastar Updates Executive Employment Agreements to Strengthen Leadership
- Amphastar Pharmaceuticals Balances Growth Plans With Margin Risks
- Amphastar price target lowered to $30 from $34 at Wells Fargo